Literature DB >> 29413729

Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis.

Wisam Al-Bassam1, Mark Kubicki1, Michael Bailey2, Laurence Walker3, Paul Young4, David V Pilcher5, Rinaldo Bellomo6.   

Abstract

BACKGROUND: There are limited data on the characteristics, incidence, and mortality of patients with myasthenia gravis (MG) admitted to the ICU. AIMS: To study the epidemiology, characteristics and outcome of patients with MG in Australian and New Zealand (ANZ) ICUs over a decade.
METHODS: We performed a retrospective observational, cross sectional study of data from the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD). We collected data on all adult patients admitted with a primary diagnosis of MG to 159 Australian and 19 New Zealand ICUs between January 1, 2005 and December 31, 2015.We extracted detailed relevant data and performed statistical assessment.
RESULTS: We identified 245 patients admitted to ICU with the primary diagnosis of MG, with an incidence increasing from 1 to 2.5 per thousand ICU admissions (P<0.0001) and from 1 to 2.2 per million people (P=0.02). Mean age was 60years with more patients being female (53.7% vs 47.3%) and 91 (37.1%) patients received mechanical ventilation. Hospital mortality occurred in 13 (5.3%) patients with a mortality rate lower than in other ICU patients.
CONCLUSIONS: In ANZ, the ICU and population incidence of MG has increased over the last decade. However, its mortality rate was low.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Australia and New Zealand; Characteristics; Critical care outcome; Mortality; Myasthenia Gravis

Mesh:

Year:  2018        PMID: 29413729     DOI: 10.1016/j.jcrc.2018.01.003

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  1 in total

1.  Our Clinical Experience in the Treatment of Myasthenia Gravis Acute Exacerbations with a Novel Nanomembrane-Based Therapeutic Plasma Exchange Technology.

Authors:  Dimitar Tonev; Radostina Georgieva; Evgeniy Vavrek
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.